Q-omics provides the consensus-scored FAM21FP profile across patient tissues and cancer cell-line models. FAM21FP expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, FAM21FP is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, FAM21FP RNA expression shows 15,771 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, LIHC, and UVM as cancer lineages where FAM21FP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM21FP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM21FP survival associations across molecular data types. FAM21FP RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM21FP RNA expression–survival associations across cancer types. High FAM21FP expression shows unfavorable associations in KICH and KIRC, but favorable associations in LUAD, THYM, PAAD and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KICH as the clearest survival context for FAM21FP RNA expression.
This table summarizes FAM21FP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM21FP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM21FP shows lower tumor expression in KICH, COAD and BRCA and higher tumor expression in LIHC, KIRP and CHOL. The LIHC box plot shows higher FAM21FP RNA expression in tumor versus normal tissue (log2 FC = +0.335, t-test p < 0.001).
This table shows molecular features associated with FAM21FP in patient tissues and cancer cell lines. In patient samples, FAM21FP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
